

# LICENSE AGREEMENT

Sangamo Therapeutics, Inc. – Novartis International AG



## GENERAL INFORMATION

<b>Deal date:</b>	July 2020	<b>Orphan status:</b>	No
		<b>Exclusivity:</b>	Yes
<b>Type of agreement:</b>	Licensing - technology / platform	<b>Type of collaboration:</b>	Co-development, Co-marketing
<b>Licensor:</b>	Sangamo Therapeutics, Inc.	<b>Licensee:</b>	Novartis International AG

### Agreement description:

Sangamo Therapeutics, Inc. entered a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo's genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders.

**Territory including** Worldwide

**Sources:** Press release [Download PDF](#) [View in Browser](#)  
Sangamo, Novartis Partner to Develop Gene Therapies for Autism

## COMPOUND INFORMATION

**Compound Name:** ZFP-TF genome regulation technology

### Compound details:

ZFP-TF genome regulation technology, which is currently delivered with adeno-associated viruses (AAVs), functions at the DNA level to selectively repress or activate the expression of specific genes to achieve a desired therapeutic effect.

## DISEASE INFORMATION

**Main indication:** Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified.

**Sub indication:** Autism

**Clinical Phase:** n/a

## MILESTONES & ROYALTIES

<b>Deal size:</b>	USD 795.00 million
<b>Upfront payments:</b>	USD 75.00 million
<b>Upfront remarks:</b>	Novartis payed USD 75 million upfront.
<b>Total milestone amount:</b>	USD 720.00 million
<b>Milestone remarks:</b>	Sangamo received USD 720 million in other development and commercial milestone payments.
<b>Royalties:</b>	Yes, but amount not available
<b>Royalties remarks:</b>	Sangamo received USD 720 million in other development and commercial milestone payments.